Navigation Links
FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension
Date:5/26/2009

Conference Call to be Held at 9:00 a.m. Eastern Time Today, May 26, 2009

SILVER SPRING, Md., May 26 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that the United States Food and Drug Administration (FDA) has approved ADCIRCA(TM) (tadalafil) tablets for oral administration, with a recommended dose of 40 mg, as the first once-daily phosphodiesterase type 5 (PDE5) inhibitor for the treatment of pulmonary arterial hypertension (PAH). ADCIRCA is indicated to improve exercise ability in WHO Group I PAH patients, which encompasses patients with multiple forms of PAH including etiologies such as idiopathic and familial PAH as well as PAH associated with scleroderma and congenital heart disease.

"Today, thanks to the clinical development efforts led by Eli Lilly & Company, we are thrilled to make available an effective, convenient and economical therapy for PAH patients," said Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "The FDA's action in approving once-a-day ADCIRCA is a big plus for all three P's: patients, physicians and payors."

In the PHIRST-1 randomized, double-blind, 16-week placebo-controlled Phase 3 clinical trial of ADCIRCA for PAH, patients taking ADCIRCA 40 mg (administered as two 20 mg tablets) once daily achieved a 33 meter improvement in six-minute walk distance compared to the placebo group. In addition, PHIRST-1 patients taking ADCIRCA 40 mg experienced less clinical worsening (defined as death, lung transplantation, atrial septostomy, hospitalization because of worsening PAH, initiation of new PAH therapy, or worsening WHO functional class) compared to the placebo group. The most common adverse events in the trial were generally transient, mild to moderate in intensity and included headache, muscle pain, flushin
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
2. FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
3. FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation
4. FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain
5. FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder
6. FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes
7. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
8. F.D.A. Approves SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy
9. FDA Approves First Hepatitis B Viral Load Test
10. U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinsons Disease
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... LINCOLNSHIRE, Ill. , July 29, 2014  Sysmex ... equipment and information systems technology, will feature an exhibit ... (AACC) Annual Meeting and Clinical Lab Expo in ... 31, 2014. "We are extremely excited ... tremendous opportunity to interact with our customers and continue ...
(Date:7/29/2014)... LAKE CITY , July 29, 2014  The ... The Grand American Hotel in Salt Lake ... speakers representing some of most respected healthcare organizations in ... Health Catalyst , is an industry conference devoted to ... healthcare analytics,  an essential element of both accountable care ...
(Date:7/29/2014)...  Novation, a VHA and UHC company, today ... features that automate key health care supply chain ... Association.  The new and enhanced ... Value Analysis, Item Master and Formulary – are ... most critical challenges brought on by health care ...
Breaking Medicine Technology:New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 2New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 3Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 2Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 3Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 4Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 5Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 2Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 3Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 4Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 5
... Pharmaceuticals (Nasdaq: ENDP ) will announce its third ... host a conference call and webcast at 10:00 a.m. ET ... P. Holveck, president and CEO of Endo, Julie McHugh, chief ... Alan Levin, executive vice president and chief financial officer, and ...
... FUJIFILM Medical Systems U.S.A., Inc. is pleased to announce ... flat panel detector (FPD). This addition to the FDR D-EVO ... vendor to provide a 17 x 17 inch wireless, flat ... solutions for nearly any general radiology exam is proven by ...
Cached Medicine Technology:Endo Pharmaceuticals to Announce Third Quarter 2011 Financial Results on October 27, 2011 2Fujifilm Expands FDR D-EVO™ Wireless Product Line With New 17x17 Inch Detector 2Fujifilm Expands FDR D-EVO™ Wireless Product Line With New 17x17 Inch Detector 3
(Date:7/29/2014)... (PRWEB) July 29, 2014 Many people complain ... thing they do each morning is put on glasses to ... These same individuals also may be dissatisfied with their ... , Cataracts may cause difficulty driving, especially at night ... follow or find one’s golf ball, see the TV, sew ...
(Date:7/29/2014)... LA (PRWEB) July 29, 2014 Historically, ... across the United States usually celebrated throughout that time ... though, those summer days now mark the start of ... crashes involving teen drivers. In 2012 nearly 1.000 ... the period from Memorial Day to Labor Day. , ...
(Date:7/29/2014)... 2014 Avenidas is always looking ... Once again, the non-profit agency is doing just that with ... seniors. , This event gives seniors the opportunity to learn ... There will be a variety of fun activities, including a ... demonstrations and artists. In addition, there will be food tastings, ...
(Date:7/29/2014)... July 29, 2014 Summer is here, and that ... enjoying a hike, swimming in a pool or laying out on ... fleas and ticks. The Puppy Store is here to help pet ... months. , It’s almost impossible to completely keep fleas and ticks ... minimize the chances of their pets coming into contact with fleas ...
(Date:7/29/2014)... headache sufferers to record the severity and regularity of ... Griffith research study. , A new approach to the ... with their triggers and is being led by Professor ... Health program. , He has developed an approach designed ... their headaches called Learning to Cope with Triggers (LCT). ...
Breaking Medicine News(10 mins):Health News:Cataract Surgery: New Technology for Reduced Dependence on Glasses 2Health News:Narconon New Life Retreat Launches New Alcohol Prevention Program 2Health News:Avenidas Hosts Third Annual Successful Aging Celebration 2Health News:Protect Dogs From Fleas and Ticks During the Summer 2
... New web-based research has quantified the attractiveness of the ... features of one woman into 243 variations with differing ... widths. Then more than 34,000 people judged the attractiveness ... the same in all of the photos, researchers found ...
... Old Republic International Corporation (NYSE: ORI ... the payment of the regular quarterly cash dividend of 17 ... March 13, 2009 to shareholders of record on March 4, ... rate initially approved for the second quarter of 2008. ...
... as Asian AffiliateNEW YORK and SINGAPORE, Feb. 26 ... prevention services, has signed an affiliation agreement with ... group based in Singapore and a subsidiary of ... medicine programs throughout Asia. Under the agreement, ParkwayHealth ...
... 274 adults with intellectual disabilities currently receiving funding ... , Washington, DC(February 23, 2009)The Supports Intensity ... for people with intellectual disability based on individual ... tool, unlike adaptive behavior instruments or other measures ...
... at the UCSF-Gladstone Institute for Virology and Immunology Center ... development of the next generation of HIV/AIDS researchers and ... published in the American Journal for Public Health ... of the AJPH website, the program focuses on overcoming ...
... Abbott ( NYSE: ABT ),today announced that it has ... now a wholly owned subsidiary of Abbott and has been,renamed ... acquisition of AMO enhances and strengthens Abbott,s diverse mix of,medical ... large and,growing eye care market. Abbott Medical Optics holds ...
Cached Medicine News:Health News:Plastic and reconstructive surgery ... in brief 2Health News:U.S. Preventive Medicine(R), ParkwayHealth Sign Affiliation Agreement to Jointly Deliver Preventive Medicine Services in Asia 2Health News:U.S. Preventive Medicine(R), ParkwayHealth Sign Affiliation Agreement to Jointly Deliver Preventive Medicine Services in Asia 3Health News:Supports Intensity Scale is effective for identifying needs in people with intellectual disability 2Health News:Effective mentoring critical to HIV/AIDS research efforts 2Health News:Abbott Completes Acquisition of Advanced Medical Optics 2
... is a three-part differential control assayed for all ... Series, T Series, AcT/AcT diff/AcT diff2, MD Series ... 1700, and 1800; Danam Datacell18, Datacell 18MS/18MS Plus, ... PLUS and I-1600; the ABX Micros 60, and ...
... Plus Retics is a 5-part differential control ... the Coulter GENS, STKS, LH 750/LH 755, ... automated and manual reticulocyte values for all ... reticulocyte percentages vary and are within clinically ...
... is a gene expression ... the risk of metastasis ... It is based on ... the Netherlands Cancer Institute ...
Abiomed introduces its new intra-aortic balloon (IAB); an easy-to-insert, minimally invasive technology designed to enhance blood flow to the heart and other organs for patients with diminished heart...
Medicine Products: